Sendag Yaslıkaya

8PUBLICATIONS
50CO-AUTHORS
Predictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 26, 2026
Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?

|Sep 15, 2026
EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study.

|Aug 27, 2026
Quantitative Immunohistochemical Landscapes and Chemoimmunotherapy Outcomes of ASCL1, NEUROD1, POU2F3, and YAP1 in Pure Small-Cell Lung Cancer: A Pilot Study.

|Jul 15, 2026
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

|Jun 12, 2026
Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.

|Mar 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek

Pageof 2

Frequent Collaborators

6 joint publications

Ertugrul Bayram

6 joint publications

Yasemin Aydınalp Camadan

5 joint publications

Suheda Atas Ipek

4 joint publications

Hatice Asoglu